A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma
Status:
Withdrawn
Trial end date:
2018-09-10
Target enrollment:
Participant gender:
Summary
Expression of IDO and PD-1/L1 has been found to be increased in endometrial cancer.
Expression of these markers on the tumor cells leads to immunosuppression in the
micro-environment of tumors that prevents immune system from attacking and killing tumor
cells. The purpose of this trial is to target these antigens by concomitant administration of
drugs epacadostat and pembrolizumab, thereby removing twin mechanisms of immune-suppression
that may lead to better control of tumor growth.